|
Market Closed -
London S.E.
11:35:02 2026-08-28 EDT
|
5-day change | 1st Jan Change | ||
| 0.1550 GBX | 0.00% |
|
0.00% | -53.73% |
| 08-10 | ValiRx subsidiary Cytolytix nears "significant" European patent win | AN |
| 08-10 | ValiRx Unit Receives Intention to Grant European Patent for Anti-Cancer Peptide | MT |
Company Valuation: ValiRx plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 12.65 | 23.58 | 9.107 | 6.037 | 2.901 | 2.488 |
| Change | - | 86.37% | -61.38% | -33.71% | -51.94% | -14.24% |
| Enterprise Value (EV) 1 | 10.88 | 23.05 | 8.007 | 5.884 | 1.357 | 1.698 |
| Change | - | 111.89% | -65.25% | -26.51% | -76.94% | 25.11% |
| P/E | -5.12x | -15.5x | -4.57x | -2.94x | -0.53x | -0.62x |
| PBR | 2.58x | 6.55x | 3.12x | 1.88x | 0.67x | 0.87x |
| PEG | - | 0.4x | -0.1x | 0.1x | 0x | 0x |
| Capitalization / Revenue | - | - | - | 628,839,167x | 58,286,328x | 79,310,054x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -7.64x | -15.8x | -3.35x | -2.87x | -0.72x | -1.07x |
| EV / EBIT | -6.59x | -13.7x | -3.09x | -2.56x | -0.63x | -0.93x |
| EV / FCF | -6.31x | -30.1x | -8.6x | -4.12x | -1.46x | -1.74x |
| FCF Yield | -15.9% | -3.32% | -11.6% | -24.3% | -68.5% | -57.4% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0381 | -0.0234 | -0.0306 | -0.0201 | -0.0145 | -0.005397 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | 0.0096 | 0.0498 | 0.0314 |
| EBITDA 1 | -1.423 | -1.457 | -2.389 | -2.05 | -1.875 | -1.587 |
| EBIT 1 | -1.651 | -1.678 | -2.593 | -2.299 | -2.142 | -1.822 |
| Net income 1 | -1.443 | -1.518 | -2.366 | -2.038 | -1.916 | -2.232 |
| Net Debt 1 | -1.776 | -0.535 | -1.1 | -0.1526 | -1.544 | -0.7902 |
| Reference price 2 | 0.195000 | 0.362500 | 0.140000 | 0.059000 | 0.007750 | 0.003350 |
| Nbr of stocks (in thousands) | 64,882 | 65,049 | 65,049 | 102,320 | 374,349 | 742,721 |
| Announcement Date | 6/14/21 | 6/7/22 | 6/5/23 | 5/15/24 | 6/6/25 | 7/4/26 |
1GBP in Million2GBP
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 2.77M | |
| 20.59x | 7.25x | 14.66x | 1.42% | 69.54B | |
| 36.89x | 9.62x | 29.41x | 0.04% | 64.97B | |
| 30.69x | 6.58x | 17.2x | -.--% | 26.51B | |
| -74.93x | 13.98x | -67.43x | -.--% | 25.89B | |
| -15.61x | 5.94x | -7.46x | -.--% | 25.64B | |
| 58.27x | 21.67x | 43.95x | 0.26% | 20.22B | |
| 27.27x | 5.11x | 16.98x | -.--% | 19.98B | |
| 1415.29x | 39.34x | 858.54x | -.--% | 15.69B | |
| 16.84x | 5x | 11.66x | -.--% | 13.49B | |
| Average | 168.37x | 12.72x | 101.95x | 0.19% | 28.19B | |
| Weighted average by Cap. | 93.83x | 10.79x | 57.82x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- VAL Stock
- Valuation ValiRx plc
Select your edition
All financial news and data tailored to specific country editions
